GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bionoid Pharma Inc (OTCPK:BINP) » Definitions » Cash Flow from Financing

Bionoid Pharma (Bionoid Pharma) Cash Flow from Financing : $2.42 Mil (TTM As of Mar. 2011)


View and export this data going back to 2007. Start your Free Trial

What is Bionoid Pharma Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2011, Bionoid Pharma paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $0.02 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Bionoid Pharma spent $0.02 Mil on financial activities for the three months ended in Mar. 2011.


Bionoid Pharma Cash Flow from Financing Historical Data

The historical data trend for Bionoid Pharma's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionoid Pharma Cash Flow from Financing Chart

Bionoid Pharma Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10
Cash Flow from Financing
0.51 0.54 0.42 0.58 2.57

Bionoid Pharma Quarterly Data
Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.54 0.37 1.53 -0.02

Bionoid Pharma Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Bionoid Pharma's Cash from Financing for the fiscal year that ended in Dec. 2010 is calculated as:

Bionoid Pharma's Cash from Financing for the quarter that ended in Mar. 2011 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionoid Pharma  (OTCPK:BINP) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Bionoid Pharma's issuance of stock for the three months ended in Mar. 2011 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Bionoid Pharma's repurchase of stock for the three months ended in Mar. 2011 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Bionoid Pharma's net issuance of debt for the three months ended in Mar. 2011 was $-0.02 Mil. Bionoid Pharma spent $0.02 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Bionoid Pharma's net issuance of preferred for the three months ended in Mar. 2011 was $0.00 Mil. Bionoid Pharma paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Bionoid Pharma's cash flow for dividends for the three months ended in Mar. 2011 was $0.00 Mil. Bionoid Pharma received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Bionoid Pharma's other financing for the three months ended in Mar. 2011 was $0.00 Mil. Bionoid Pharma received $0.00 Mil on other financial activities.


Bionoid Pharma Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Bionoid Pharma's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionoid Pharma (Bionoid Pharma) Business Description

Traded in Other Exchanges
N/A
Address
433 N Camden Dr, Beverly Hills, CA, USA, 90210
Bionoid Pharma Inc is a cannabis company that cultivates, extracts, tests, and distributes organic hemp, cannabinoid, and related products. Its products aid in decreasing pain, improving recovery time, enhancing performance, and enhance physical well-being.